Concord Biotech

{
  "main_header": {
    "sid": 10038977,
    "name": "Concord Biotech",
    "stock_name": "Concord Biotech",
    "full_name": "Concord Biotech Ltd",
    "name_url": "stocks-analysis/concord-biotech",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,367.60",
    "chg": -7.4,
    "chgp": "-0.54%",
    "dir": -1,
    "prev_price": "1,375.00",
    "mcapval": "14,462.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543960,
    "symbol": "CONCORDBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE338H01029",
    "curr_date": "Aug 07, 03:30 PM",
    "curr_time": "02:14 AM",
    "last_traded_at": "Aug 07, 03:30 PM IST",
    "bse_nse_vol": "77.7 k",
    "exc_status": "Active",
    "traded_date": "Aug 07, 2026",
    "traded_date_str": "2026 08 07",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/concord-biotech-10038977-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Biotech Declines 3.71% Despite Technical Upgrade: 5 Key Insights from the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-declines-371-despite-technical-upgrade-5-key-insights-from-the-week-4143009",
        "imagepath": "",
        "date": "2026-08-08 11:02:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>3 Aug:</strong> Mojo Grade upgraded to Hold on technical improvements</p>\n                    <p><strong>3 Aug:</strong> Strong 6.53% intraday gain signalling momentum shift</p>\n                    <p><strong>5 Aug:</strong> Sharp 2.73% decline amid mixed market conditions</p>\n                    <p><strong>7 Aug:</strong> Week closes at Rs.1,367.60, down 3.71%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,420.30</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,367.60</div><di..."
      },
      {
        "title": "Concord Biotech Ltd Upgraded to Hold by MarketsMOJO on Technical Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-ltd-upgraded-to-hold-by-marketsmojo-on-technical-improvements-4133074",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/ConcordBiotechL_mojoScore_4133074.png",
        "date": "2026-08-03 08:13:55",
        "description": "Concord Biotech Ltd has seen its investment rating upgraded from Sell to Hold as of 31 July 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s technical trend has improved from mildly bearish to mildly bullish, prompting a reassessment of its outlook. However, the upgrade comes amid mixed signals from its financial performance and valuation metrics, reflecting a nuanced investment case for this small-cap pharmaceutical player."
      },
      {
        "title": "Concord Biotech Ltd Shows Technical Momentum Shift Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-ltd-shows-technical-momentum-shift-amid-mixed-market-signals-4132997",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/ConcordBiotechL_technicaldot_4132997.png",
        "date": "2026-08-03 08:03:44",
        "description": "Concord Biotech Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bearish stance to a cautiously optimistic mildly bullish trend. This change is underscored by a 6.53% gain in the stock price on 3 Aug 2026, reflecting renewed investor interest amid mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages."
      },
      {
        "title": "Concord Biotech Q1 FY27: Strong Growth Marred by Sequential Decline and Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/concord-biotech-q1-fy27-strong-growth-marred-by-sequential-decline-and-valuation-concerns-4131853",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/ConcordBiotech_quaterlyResult_4131853.png",
        "date": "2026-08-01 13:19:55",
        "description": "Concord Biotech Limited, a specialty pharmaceutical company focused on fermentation-based active pharmaceutical ingredients, reported a mixed performance for Q1 FY27, with consolidated net profit reaching ₹58.53 crores, representing a year-on-year growth of 32.84% but a sequential decline of 34.08% from the preceding quarter. The stock surged 6.53% on July 31, 2026, closing at ₹1,420.30, reflecting market optimism despite the company's ₹14,247 crore market capitalisation trading at premium valuations."
      },
      {
        "title": "Are Concord Biotech Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-concord-biotech-ltd-latest-results-good-or-bad-4130686",
        "imagepath": "",
        "date": "2026-07-31 19:22:26",
        "description": "Concord Biotech Ltd's latest financial results for the quarter ending March 2026 reveal a complex operational landscape. The company reported a net profit of ₹88.79 crores, which reflects a significant year-on-year decline of 36.75%, although there was a sequential improvement of 37.70% compared to the previous quarter. Similarly, net sales amounted to ₹326.08 crores, showing a year-on-year decrease of 24.15%, but a quarter-on-quarter increase of 17.39%.\n\nThe operating margin for the quarter stood at 36.35%, down from 44.30% in the same quarter last year, indicating substantial margin compression due to rising operational costs and pricing pressures in key markets. The profit after tax margin also contracted to 27.13%, down from 32.66% year-on-year, highlighting ongoing challenges in maintaining profitability.\n\nFor the full fiscal year FY26, consolidated revenues reached ₹1,054.90 crores, with a net profit ..."
      },
      {
        "title": "Golden Cross Forms in Concord Biotech Ltd — Mixed Technical Signals and Fundamental Context",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4130563",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ConcordBiotechL_goldencross_4130563.png",
        "date": "2026-07-31 18:00:42",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Concord Biotech Ltd, signalling a golden cross on 31 Jul 2026. Yet, the stock’s technical indicators and fundamental backdrop present a nuanced picture that tempers the enthusiasm typically associated with this crossover."
      },
      {
        "title": "When is the next results date for Concord Biotech Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-concord-biotech-ltd-4127654",
        "imagepath": "",
        "date": "2026-07-29 23:17:29",
        "description": "The next results date for Concord Biotech Ltd is scheduled for 31 July 2026...."
      },
      {
        "title": "Concord Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-ltd-is-rated-sell-4120279",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ConcordBiotechL_mojoScore_4120279.png",
        "date": "2026-07-25 10:10:04",
        "description": "Concord Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 July 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "Concord Biotech Ltd Faces Mildly Bearish Momentum Amid Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-ltd-faces-mildly-bearish-momentum-amid-technical-shifts-4111792",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ConcordBiotechL_technicaldot_4111792.png",
        "date": "2026-07-21 08:07:44",
        "description": "Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in price momentum, with technical indicators signalling a transition from sideways to mildly bearish trends. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s mixed technical signals warrant a detailed analysis for investors navigating this evolving landscape."
      }
    ],
    "total": 437,
    "sid": "10038977",
    "stock_news_url": "https://www.marketsmojo.com/news/concord-biotech-10038977"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "07-Aug-2026",
      "details": "Transcript of Q1 - FY27 Earnings call held on August 03 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "03-Aug-2026",
      "details": "The audio recording of the conference held on August 03 2026 has been hosted on the website of the company and link to access the said recording is as follows: - Link : https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Aug-2026",
      "details": "Newspaper publication cutouts of unaudited Standalone and Consolidated Financial results for the first quarter ended June 30 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Concord Biotech Ltd has declared <strong>755%</strong> dividend, ex-date: 24 Jul 26",
          "dt": "2026-07-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Concord Biotech Declines 3.71% Despite Technical Upgrade: 5 Key Insights from the Week

2026-08-08 11:02:42

Key Events This Week

3 Aug: Mojo Grade upgraded to Hold on technical improvements

3 Aug: Strong 6.53% intraday gain signalling momentum shift

5 Aug: Sharp 2.73% decline amid mixed market conditions

7 Aug: Week closes at Rs.1,367.60, down 3.71%

Week Open

Rs.1,420.30

Week Close

Rs.1,367.60

Read full news article

Concord Biotech Ltd Upgraded to Hold by MarketsMOJO on Technical Improvements

2026-08-03 08:13:55

Concord Biotech Ltd has seen its investment rating upgraded from Sell to Hold as of 31 July 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s technical trend has improved from mildly bearish to mildly bullish, prompting a reassessment of its outlook. However, the upgrade comes amid mixed signals from its financial performance and valuation metrics, reflecting a nuanced investment case for this small-cap pharmaceutical player.

Read full news article

Concord Biotech Ltd Shows Technical Momentum Shift Amid Mixed Market Signals

2026-08-03 08:03:44

Concord Biotech Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bearish stance to a cautiously optimistic mildly bullish trend. This change is underscored by a 6.53% gain in the stock price on 3 Aug 2026, reflecting renewed investor interest amid mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages.

Read full news article

Concord Biotech Q1 FY27: Strong Growth Marred by Sequential Decline and Valuation Concerns

2026-08-01 13:19:55

Concord Biotech Limited, a specialty pharmaceutical company focused on fermentation-based active pharmaceutical ingredients, reported a mixed performance for Q1 FY27, with consolidated net profit reaching ₹58.53 crores, representing a year-on-year growth of 32.84% but a sequential decline of 34.08% from the preceding quarter. The stock surged 6.53% on July 31, 2026, closing at ₹1,420.30, reflecting market optimism despite the company's ₹14,247 crore market capitalisation trading at premium valuations.

Read full news article

Are Concord Biotech Ltd latest results good or bad?

2026-07-31 19:22:26

Concord Biotech Ltd's latest financial results for the quarter ending March 2026 reveal a complex operational landscape. The company reported a net profit of ₹88.79 crores, which reflects a significant year-on-year decline of 36.75%, although there was a sequential improvement of 37.70% compared to the previous quarter. Similarly, net sales amounted to ₹326.08 crores, showing a year-on-year decrease of 24.15%, but a quarter-on-quarter increase of 17.39%. The operating margin for the quarter stood at 36.35%, down from 44.30% in the same quarter last year, indicating substantial margin compression due to rising operational costs and pricing pressures in key markets. The profit after tax margin also contracted to 27.13%, down from 32.66% year-on-year, highlighting ongoing challenges in maintaining profitability. For the full fiscal year FY26, consolidated revenues reached ₹1,054.90 crores, with a net profit ...

Read full news article

Golden Cross Forms in Concord Biotech Ltd — Mixed Technical Signals and Fundamental Context

2026-07-31 18:00:42

The 50-day moving average has crossed above the 200-day moving average for Concord Biotech Ltd, signalling a golden cross on 31 Jul 2026. Yet, the stock’s technical indicators and fundamental backdrop present a nuanced picture that tempers the enthusiasm typically associated with this crossover.

Read full news article

When is the next results date for Concord Biotech Ltd?

2026-07-29 23:17:29

The next results date for Concord Biotech Ltd is scheduled for 31 July 2026....

Read full news article

Concord Biotech Ltd is Rated Sell

2026-07-25 10:10:04

Concord Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 July 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Read full news article

Concord Biotech Ltd Faces Mildly Bearish Momentum Amid Technical Shifts

2026-07-21 08:07:44

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in price momentum, with technical indicators signalling a transition from sideways to mildly bearish trends. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s mixed technical signals warrant a detailed analysis for investors navigating this evolving landscape.

Read full news article

View All News